Quantitative T2 mapping of glenohumeral joint osteoarthritis: a case-control study

Abstract

Background: T2 relaxometry is a highly sensitive technique used to assess morphological changes in the cartilage prior to anatomical changes; it provides the quantification of the disparate components of cartilage such as water, proteoglycans, and collagen. This study aims to assess T2 values of glenohumeral joint cartilage using 1.5 T magnetic resonance imaging (MRI) and comparing T2 relaxation time values between two groups—the control group and the group of patients with osteoarthritis (OA). The study was conducted among 35 OA patients (27 females and eight males; median age, 60 years; age range, 43–69 years). This group was divided into primary OA (n = 15) and secondary OA (n = 20). The control group had 30 patients (25 females and five males; median age, 46 years; age range, 30–56 years). All patients were assessed using plain radiography to determine the grade of osteoarthritis followed by a multi-echo spin pulse sequence (T2 mapping) of the coronal plane. Three areas were considered to evaluate the cartilage-humeral zone, glenoid zone, and central zones by manually drawing the region of interest (ROI). The values were compared statistically by using Mann-Whitney U tests. Results: Median T2 values differed significantly between the control group (43.4 ms [interquartile ranges, 41.54-45.33 ms]) and the OA patients for grades I (59.2 ms [interquartile ranges, 57.54-63.33 ms]), II (64.7 ms [interquartile ranges, 62.54-67.39 ms]), and III (61.9 ms, [interquartile ranges, 57.54-64.53 ms]). Mean T2 values were significantly higher in the different zones when comparing the OA patients whatever the cause primary or secondary (p value < 0.05) with the control group; no significant difference was noticed between the primary and secondary OA (p value > 0.05). Conclusion: T2 relaxometry is a reliable, quantitative method for the assessment of the glenohumeral cartilage for significant differences in T2 values between the control group and the OA patients.